Yokogawa Corporation of America and Repligen have entered into a strategic partnership to integrate Yokogawa’s OpreX Bio Pilot with Repligen’s MAVERICK® platform. This collaboration aims to enhance automated control of critical nutrients—specifically glucose and lactate—in cell cultures, a key factor in advancing process analytical technology (PAT).
By combining these technologies, scientists can continuously monitor and manage essential process parameters without developing complex calibration models or relying on manual sampling. This real-time, automated approach ensures more accurate data management, offering greater consistency and efficiency in bioprocess development.
In biopharmaceutical research, maintaining optimal glucose and lactate levels is vital for cell culture performance, directly influencing product yield, quality, and reliability. The new integration enables precise control of bioreactor environments, reducing the risk of batch failures, increasing productivity, and shortening time-to-market for novel therapies.
Early scientific findings showcasing the benefits of this collaboration—merging real-time analytics with digital bioprocessing—will be presented by Yokogawa at BioProcess International 2025, scheduled for September 17th. Demonstrations are already underway at Yokogawa’s laboratory in Tokyo, Japan, and Repligen’s facility in Waltham, Massachusetts, with further studies planned at additional research sites worldwide.